FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes

Thomas Laeger1,2 · Christian Baumeier1,2 · Ilka Wilhelmi1,2 · Josefine Würfel1,2 · Anne Kamitz 1,2 · Annette Schürmann1,2

Abstract
Aims/hypothesis Fibroblast growth factor 21 (FGF21) is considered to be a promising therapeutic candidate for the treatment of type 2 diabetes. However, as FGF21 levels are elevated in obese and diabetic conditions we aimed to test if exogenous FGF21 is sufficient to prevent diabetes and beta cell loss in New Zealand obese (NZO) mice, a model for polygenetic obesity and type 2 diabetes.

Methods Male NZO mice were treated with a specific dietary regimen that leads to the onset of diabetes within 1 week. Mice were treated subcutaneously with PBS or FGF21 to assess changes in glucose homeostasis, energy expenditure, food intake and other metabolic endpoints.

Results FGF21 treatment prevented islet destruction and the onset of hyperglycaemia, and improved glucose clearance. FGF21 increased energy expenditure by inducing browning in subcutaneous white adipose tissue. However, as a result of a compensatory increased food intake, body fat did not decrease in response to FGF21 treatment, but exhibited elevated Glut4 expression.

Conclusions/interpretation FGF21 prevents the onset of diet-induced diabetes, without changing body fat mass. Beneficial effects are mediated via white adipose tissue browning and elevated thermogenesis. Furthermore, these data indicate that obesity does not induce FGF21 resistance in NZO mice.

Keywords Energy expenditure · FGF21 · Glucose homeostasis · Insulin resistance · NZO · Obesity · Thermogenesis · UCP1

Introduction
Type 2 diabetes mellitus is a complex disease characterised by insufficient secretion of insulin from pancreatic beta cells (beta cell failure) in the setting of insulin resistance. Before the onset of type 2 diabetes beta cells start to proliferate and increase the biosynthesis and secretion of insulin to compensate for peripheral insulin resistance and glucose intolerance [1]. Eventually, due to a decline in the secretory rate and a decrease in beta cell mass, impaired insulin secretion fails to compensate, resulting in hyperglycaemia, beta cell destruction and type 2 diabetes. Causes of beta cell loss are chronic hyperglycaemia (glucotoxicity) and chronically elevated...
NEFA and lipid intermediates (lipotoxicity) [2]. Therefore, current research efforts are focused on new strategies to improve insulin sensitivity and protect beta cells against glucolipotoxicity.

Fibroblast growth factor (FGF) 21 is an endocrine hormone that has, besides its primary function of maintaining the energy homeostasis, beneficial effects on glucose homeostasis, including weight loss. Circulating FGF21 is primarily derived from the liver, but is also expressed in the gut, brain, adipose tissue, muscle and pancreas [3–5]. FGF21, which is widely considered to be induced by fasting, is the first known endocrine signal that is activated by protein restriction rather than energy deprivation [3, 4, 6]. Although FGF21 is robustly elevated in low-protein environments, increased FGF21 is also seen in various other contexts such as fasting, overfeeding, ketogenic diets and high-carbohydrate diets [7]. FGF21 signals through a cell-surface receptor complex composed of both the traditional FGF receptor (FGFR) 1c and the FGF co-receptor β-klotho [8]. Many studies have revealed the critical role of β-klotho as a cofactor essential for FGF21-mediated signalling [8–11].

FGF21 targets a variety of different organs. As recently reviewed in [12, 13], exogenously administered FGF21 acts directly on adipose tissue to reduce blood glucose levels and increase hepatic, and possibly peripheral, insulin sensitivity, decrease body weight and decrease serum lipids [14]. In adipocytes, FGF21 induces GLUT1 expression and glucose uptake [15]. FGF21 treatment activates browning of white adipose tissue (WAT), and increases thermogenesis in brown adipose tissue (BAT) and WAT [16]. Administration of FGF21 directly into the brain has been shown to induce activation of BAT, and to increase energy expenditure (EE) and insulin sensitivity [17, 18]. In the pancreas, FGF21 has been shown to improve beta cell function and survival [19], suppress islet glucagon secretion [20] and prevent pancreatic inflammation [21]. FGF21 stimulates insulin secretion in ex vivo islets isolated from rodent models of diabetes [19], but does not affect insulin secretion from islets isolated from healthy mice [22]. In the liver, FGF21 is reported to increase NEFA turnover and to reduce lipogenesis and glucose output, as recently summarised in [18].

Its beneficial roles in regulating insulin sensitivity and glucose homeostasis make FGF21 a promising therapeutic candidate for the treatment of diabetes [23]. However, obesity is thought to be an FGF21-resistant state because of the elevated endogenous FGF21 levels [24, 25]. Serum FGF21 concentrations were elevated in obese and diabetic rodent models in comparison with lean controls [20, 26, 25]. In addition, in relation to normal lean individuals, FGF21 was up to 2.0-fold higher in people with obesity and type 2 diabetes [27, 28]. Obese monkeys display high levels of FGF21 and reduced levels of β-klotho in adipose tissue, whereas monkeys that maintained normal levels of β-klotho are protected against obesity [29]. Interestingly, downregulation of β-klotho expression is not the major mechanism contributing to impaired FGF21 signalling in WAT [30]. In contrast to a few studies suggesting FGF21 resistance, numerous studies [20, 26, 31, 32] conducted in obese animals, which may have impaired FGF21 signalling in response to physiological levels of FGF21, show a protective metabolic function in regard to pharmacological levels of exogenous FGF21. Hale et al [31] successfully challenged this hypothesis and concluded that an overt FGF21 resistance was not evident in mouse models of obesity and insulin resistance. Treatment of obese, hyperglycaemic, insulin-resistant and leptin-deficient B6-ob/ob mice with FGF21 could normalise hyperglycaemia despite markedly elevated endogenous FGF21 levels [31]. Therefore, it appears that the elevated plasma FGF21 levels under pathological conditions represent an FGF21 resistance but they are a compensatory response.

Because of this obvious contradiction, we aimed to confirm in a model for polygenic obesity and diabetes, the New Zealand obese (NZO) mouse, the beneficial effects of FGF21 that have been observed in other models. The NZO mouse displays a characteristic trait of beta cell loss [33] in contrast to other obese mouse models, e.g. B6-ob/ob mice are rescued by beta cell hyperplasia caused by a chronic glucose challenge (i.e. they are diabetes resistant). Here we investigate the effects of exogenous administration of FGF21 to obese and insulin-resistant NZO mice, and evaluate the potential of the diabetes-susceptible NZO mouse as an animal model to study endogenous FGF21 actions in regard to the prevention of diabetes in the future.

Methods

Animals and diets All procedures involving animals were approved by the animal welfare committees of the German Institute of Human Nutrition (DIfE) and the local authorities (Landesamt für Umwelt, Gesundheit und Verbraucherschutz, Brandenburg, Germany). The NZO/HIBomDife mice (German Institute of Human Nutrition, Nuthetal, Germany) were single-housed in 12:12 h light:dark cycle (lights on at 06:00 hours) at a temperature of 21 ± 1°C with ad libitum access to food and water unless otherwise noted. To investigate if the plasma FGF21 levels correlate with the blood glucose levels in NZO mice, male NZO mice received (after weaning at 3 weeks of age) a high-fat diet containing 45% (of total energy) fat, 35% carbohydrate and 20% protein (D12451, Research Diets, New Brunswick, NJ, USA). To test the ability of FGF21 to prevent diabetes we used another group of mice and treated them with a specific dietary regimen that leads to the onset of diabetes within 1 week [33–36]. Male NZO mice received (after weaning at 3 weeks of age) a standard chow diet for 2 weeks. At 5 weeks of age, mice were
placed on a carbohydrate-free high-fat (−CH) diet (32% [wt/wt] protein, 0% [wt/wt] carbohydrate and 31% [wt/wt] fat; 16.8 kJ/g; #105789, Altromin, Lage, Germany) for 13 weeks, at which point a random subgroup of animals was transferred to a carbohydrate-containing high-fat (+CH) diet (20% [wt/wt] protein, 40% [wt/wt] carbohydrate and 28% [wt/wt] fat; 21.9 kJ/g). A detailed dietary composition is provided in the electronic supplementary material (ESM) Table 1. At the end of this study, mice were killed during the mid-light cycle in a 4 h fasted state using acute exposure to isoflurane followed by rapid exsanguination via vena cava blood collection. Blood was centrifuged at 10,000 g at 4°C for 10 min. Tissues were collected and snap-frozen in liquid nitrogen for further analysis.

**Experimental design** At 5 weeks of age, male NZO mice were placed on a −CH diet for 13 weeks, at which point a random subgroup of animals was transferred to a +CH diet for 2 weeks. Animals were treated twice daily with s.c. PBS (pH 7.4) or rhFGF21 in PBS (1 μg/g bodyweight; no. CYT-474; ProSpec, East Brunswick, NJ, USA) starting 3 days before and ending 7 days after the diet switch. An OGTT was performed 8 days after the diet switch. After an overnight 16 h fasting period, mice received 2 mg glucose per g body weight via oral gavage. At the indicated points of time, blood glucose and plasma insulin were measured. Body weight and food intake were measured daily. Body composition was analysed via quantitative magnetic resonance (EchoMRI 2012 Body Composition 115 Analyzer, Houston, TX, USA) 6 days before the diet switch, at the beginning of experimental diets (day 0), on the final day of PBS or rhFGF21 treatment (day 7) and on the day of euthanisation (day 14). Random blood glucose and equivalent serum insulin levels were measured from tail blood every 2–3 days throughout the experiment. Fourteen days after the diet switch, mice fasted for 4 h were treated s.c. with PBS or rhFGF21 (1 μg/g bodyweight) 30 min before being killed. For analysis of EE and respiratory exchange ratio (RER), the transition to diet switch occurred within metabolic chambers (PhenoMaster/LabMaster; TSE Systems, Bad Homburg, Germany). Mice were treated as described before. Body weight and food intake were measured daily. Two days after the diet switch, mice fasted for 4 h were killed and tissues collected.

**Determination of FGF21 and insulin** Concentrations of mouse and recombinant human FGF21 in plasma were determined by specific ELISAs according to the procedure recommended by the manufacturer (no. RD291108200R, mouse and rat FGF-21 ELISA; no. RD191108200R, human FGF21 ELISA; BioVendor, Brno, Czech Republic) and as described previously [3, 4]. Plasma insulin concentrations were determined with an ELISA (80-INSMSU-E01; ALPCO Diagnostics, Salem, NH, USA) [37].

**Western immunoblot analysis** Western blot analysis was performed as described previously [35] using 20 μg sample solutions, 12% polyacrylamide gels, 0.45 μm pore size polyvinylidene difluoride (PVDF) membranes (Immobilon-P; Merck Millipore, Billerica, MA, USA), appropriate primary antibodies against extracellular signal-regulated kinase 1/2 (ERK1/2; 1:1000; no. 4695; Cell Signaling, Danvers, MA, USA), phosho-ERK1/2 (1:1000; no. 4377; Cell Signaling) and GAPDH (1:25,000; no. AM4300; ThermoFisher, Waltham, MA, USA), and secondary antibodies (horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgG; 1:20,000). Bands were quantified using FusionCapt Advance Solo4 v16.07 software (Vilber Lourmat, Eberhardzell, Germany). The level of phosphorylation of ERK was calculated relative to the total amount of this enzyme.

**Immunohistochemistry of pancreatic islets** Pancreatic tissue excised immediately after exsanguination was fixed in 4% (w/vol.) formaldehyde and embedded in paraffin according to standard procedures. For co-staining of insulin and glucagon, mouse monoclonal anti-insulin (1:50,000; cloneK36AC10; Sigma-Aldrich, Munich, Germany) and polyclonal goat anti-glucagon (1:50; sc-7779; Santa Cruz, Dallas, TX, USA) antibodies were used. Alexa Fluor 594-labelled donkey anti-mouse (1:200; no. A-21203; ThermoFisher) and Alexa Fluor 488-labelled donkey anti-goat (1:200; no. A11055; ThermoFisher) were used as secondary antibodies. Nuclei were stained with DAPI.

**Detection of liver triacylglycerol and glycogen concentrations** Hepatic triacylglycerol content was measured using the commercial TR-210 kit (Randox, Crumlin, UK) according to the manufacturer’s protocol. Quantification of hepatic glycogen content was performed as described before [38].

**Real-time PCR** Total RNA was extracted from liver, gonadal VAT (gWAT), subcutaneous VAT (sWAT) and BAT using RNeasy Mini Kit (Qiagen, Venlo, Netherlands) following the manufacturer’s protocol. RNA purity and quantity was determined by spectrophotometry using a NanoDrop ND-1000 (VWR, Radnor, PA, USA). cDNA synthesis was performed with M-MLV reverse transcriptase (Promega, Fitchburg, WI, USA). Amplification was performed by using the LightCycler 480 II/384 (Roche, Basel, Switzerland). Expression levels were detected by applying TaqMan Gene Expression Assays (Applied Biosystems, Waltham, MA, USA). Primer assays were designed with at least one primer spanning an exon-exon boundary. Target gene expression was normalised with Eef2 as the endogenous control.

**Statistical analysis** Data were analysed using the Prism 6 software (GraphPad Software, San Diego, CA, USA) using one-way ANOVA, two-way ANOVA or unpaired two-tailed
test. Analysis of EE with body weight as the covariate was assessed via ANCOVA using the MMPC.org ANCOVA data analysis tool. All data are expressed as mean ± SEM, with a probability value of 0.05 considered statistically significant. The experimenters were not blind to group assignment and no data were omitted.

Results

FGF21 prevents hyperglycaemia and improves glucose clearance in NZO mice

Obesity and diabetes are known for increasing circulating FGF21 levels. As expected, plasma FGF21 levels correlated positively with blood glucose levels in NZO mice (Fig. 1a, b) but a correlation between plasma FGF21 level and (c) blood glucose or (d) body weight. Gene expression of (d) Fgf21 and (e) Klb in liver, gWAT and BAT of NZO mice. White bars, blood glucose <11 mmol/l; black bars, blood glucose 11–16 mmol/l; grey bars, blood glucose >16 mmol/l. Data are presented as mean ± SEM (n = 6–9/group). Differences between groups were calculated by one-way ANOVA (a, d, e). *p < 0.05, **p < 0.01

FGF21 co-receptor β-klotho (Klb) mRNA expression was significantly decreased in BAT, but not affected in liver, gWAT or sWAT (p < 0.05; ESM Fig. 1d, e).

Plasma FGF21 concentrations in NZO mice that differ in blood glucose concentrations. Correlations between plasma FGF21 level and (b) blood glucose or (c) body weight. Gene expression of (d) Fgf21 and (e) Klb in liver, gWAT and BAT of NZO mice. White bars, blood glucose <11 mmol/l; black bars, blood glucose 11–16 mmol/l; grey bars, blood glucose >16 mmol/l. Data are presented as mean ± SEM (n = 6–9/group). Differences between groups were calculated by one-way ANOVA (a, d, e). *p < 0.05, **p < 0.01

PBS or FGF21 starting 3 days before and ending 7 days after the diet switch. While the endogenous FGF21 plasma levels did not differ between the three groups before starting the applications, human FGF21 could be successfully determined by ELISA solely in the FGF21-treated group (ESM Fig. 1a, b). Consistent with previous studies [35, 36, 39], without carbohydrates NZO mice become obese and insulin-resistant, but are protected from developing diabetes. The change to the +CH diet induced a rapid hyperglycaemia (Fig. 2b). In contrast, FGF21-treated animals exhibited normal blood glucose levels similar to PBS-treated animals kept on the −CH diet (Fig. 2b). After finishing the FGF21 treatment at day 7 on the +CH diet, blood glucose levels began to rise until the end of the study. FGF21-treated +CH-fed animals displayed normal plasma insulin levels (Fig. 2c). While the plasma insulin levels rose rapidly after the change to the +CH diet in PBS-treated mice, insulin levels began to increase robustly after termination of the FGF21 treatment in +CH-fed mice (Fig. 2c). After finishing the treatment (FGF21 and PBS) an OGTT was performed. FGF21-treated mice showed improved glucose clearance (Fig. 2d, e) with low insulin levels (Fig. 2g, h). Insulin sensitivity, as determined using the Matsuda Index (Matsuda and DeFronzo [40]), was improved by trend (p = 0.08) in +CH-fed mice treated with FGF21 (Fig. 2f). As expected, hyperglycaemic mice showed a significant increase in hepatic Fgf21 mRNA expression compared with normoglycaemic mice on the −CH diet (p < 0.05; ESM Fig. 1c) and Klb mRNA expression was significantly decreased in BAT, but not affected in liver, gWAT or sWAT (p < 0.05; ESM Fig. 1d, e).
Strikingly, FGF21 treatment induced a moderate hyperphagic response throughout the treatment independent of diet (Fig. 3a–c). At day 1 after the diet switch both PBS- and FGF21-treated NZO mice showed an increased caloric intake presumably caused by the novelty of the food (Fig. 3a). After finishing the treatment, FGF21 did not change the fat mass but decreased the lean mass by approximately 4 g (Fig. 3d–e), which led to a drop in body weight by the same extent (Fig. 3f). However, total body weight (not shown) and body weight change (Fig. 3f) did not differ between the three groups at any day throughout the experiment. Moreover, FGF21 did not affect body composition over the course of the treatment (Fig. 3g).

At the end of the study, animals fasted for 4 h were injected with PBS or FGF21, according to their former treatments, 30 min before the mice were killed to analyse ERK1/2 phosphorylation as a downstream signal for FGF21 action. As shown in ESM Fig. 1e, FGF21 treatment induced a robust increase ($p < 0.01$) in the phosphorylation of ERK1/2 in the liver, gWAT and sWAT, and a numerical increase in BAT ($p = 0.11$).

Histological analysis of the pancreatic islets at the end of the study revealed substantial islet destruction in PBS-treated +CH-fed mice, while PBS-treated −CH-fed mice displayed a normal islet morphology as expected and shown earlier [35, 36] (Fig. 4a). FGF21-treated +CH mice developed an intermediate phenotype with no disruption of normal islet
cytoarchitecture but numerically smaller amounts of synthesised insulin (Fig. 4a, b).

Final liver weight was significantly higher in +CH-fed compared with −CH-fed mice treated with PBS, probably caused by a trend of increased hepatic triacylglycerol (p = 0.10; ESM Fig. 2). While gWAT mass was significantly lower (p < 0.05) in FGF21-treated mice compared with PBS-treated mice on the +CH diet, mass of BAT was highest in FGF21-treated +CH-fed mice (p < 0.05; ESM Fig. 2a). In summary, without changes in total fat mass, FGF21 prevents hyperglycaemia and improves glucose clearance in NZO mice fed a carbohydrate-containing diet.
FGF21 increases EE in NZO mice

Studies show that pharmacological FGF21 treatment acts both in the brain and directly on adipose tissue to increase EE, stimulate sympathetic outflow and upregulate thermogenic markers in BAT and WAT [14, 17, 41, 42]. Besides increased BAT mass following FGF21 treatment (ESM Fig. 2a), FGF21-treated NZO mice showed an increased EE ($p < 0.05$) on the $-CH$ diet and an even higher EE ($p < 0.05$) on the $+CH$ diet compared with PBS-treated animals (Fig. 5a, b). Analysis of the EE data using ANCOVA with body weight as the covariant demonstrated an FGF21-dependent increase in EE (Fig. 5f, g). The RER was significantly increased by the $+CH$ diet in both PBS- and FGF21-treated mice, which reflects the expected increase in the rate of carbohydrate oxidation ($p < 0.01$; Fig. 5c, d). In contrast, there were no effects of either diet or PBS and FGF21 treatment on locomotor activity (Fig. 5e). As shown before (Fig. 3b), FGF21 treatment increased food intake in mice on the $-CH$ diet ($p < 0.01$; ESM Fig. 3a).

FGF21 induces thermogenic and lipogenic genes in sWAT and BAT in NZO mice

We next tested whether the robust increase in EE due to FGF21 was associated with changes of thermogenic markers in BAT and sWAT, which is prone to browning. Consistent with the acute increase in EE induced by FGF21, sWAT Ucp1, Cidea and Prdm16 were significantly increased ($p < 0.05$; Fig. 6a) and Dio2 mRNA expression tended to be higher ($p = 0.06$), which shows strong evidence for browning in sWAT. There was no effect of the $+CH$ diet itself on sWAT Ucp1, Cidea, Dio2 or Prdm16 mRNA expression (Fig. 6a). Feeding carbohydrate increased the mRNA expression of genes associated with lipogenesis within the sWAT (Fasn, Scd1, Acc; $p < 0.05$; Fig. 6b), whereas FGF21-treated $+CH$ mice showed even significantly higher Scd1 ($p < 0.01$) and Acc mRNA expression by trend ($p = 0.08$) compared with the PBS-treated $+CH$ mice. Interestingly, in sWAT the expression of Glut1 was not induced by FGF21, instead Glut4 mRNA expression was highest in FGF21-treated $+CH$ mice ($p < 0.05$; Fig. 6b).

Interestingly, FGF21 did not induce genes associated with thermogenesis (Cidea, Dio2) within BAT, but $+CH$ feeding significantly increased Ucp1 mRNA expression ($p < 0.05$; Fig. 6c). Lipogenic genes (Fasn, Scd1, Acc1) were significantly elevated in response to the $+CH$ diet and significantly highest due to FGF21 treatment in BAT ($p < 0.05$; Fig. 6d).
Neither the +CH diet nor FGF21 altered BAT Glut1 expression but Glut4 mRNA expression was significantly increased by the +CH diet (\(p < 0.01\); Fig. 6d). Finally, exogenous administration of FGF21 did not affect the gene expression of Fgf21 and Klb in the liver, gWAT, sWAT or BAT (Fig. 6e, f).

These data demonstrate that the effects of FGF21 on thermogenesis are intact and presumably engage UCP1-dependent increases in EE.

**Discussion**

In this study we have clearly demonstrated for the first time in obese diabetes-susceptible NZO mice with the characteristic trait of beta cell loss that exogenous treatment with FGF21 fully prevents the onset of hyperglycaemia and beta cell loss despite increased food intake without differences in the total fat mass. Recent studies have shown beneficial roles of FGF21 in regulating insulin sensitivity and glucose homeostasis. However, it has also been suggested that obesity is an FGF21-resistant state in the context of effects of endogenous levels of FGF21 [24, 25], indicating the lack of a benefit by FGF21 exposure in obese models. It is well-known that FGF21, which is primarily secreted from the liver and functions in multiple tissues, is a key endocrine regulator of glucose, lipid and energy metabolism. FGF21 activates FGFRs in the context of co-receptor \(\beta\)-klotho expression. After that, FGF21 alters ERK1/2 phosphorylation and stimulates glucose uptake. Pharmacologically administered FGF21 mediates its effects via FGF21 receptors, but individual endpoints of FGF21 pharmacology appear to be mediated by distinct downstream factors, such as adiponectin or leptin [23]. As shown by Lin et al [43], metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice are mediated by adiponectin.

As expected, NZO mice show increased FGF21 levels in particular when blood glucose levels rise. Consistent with the previously reported ability of FGF21 administration to improve hyperglycaemia and enhance insulin sensitivity and glucose clearance [19, 20, 26, 44], we observed a protection from type 2 diabetes and beta cell loss independent of body fat. The effects are mediated (1) by improving insulin sensitivity and
glucose clearance and (2) increasing the EE via browning of sWAT, which might increase glucose use via elevated Glut4 expression.

Despite a robust loss of lean mass, FGF21 treatment resulted in an improved glucose clearance supported by the Matsuda Index, which indicates improved insulin sensitivity mainly of the skeletal muscle and adipose tissue. This is supported by data showing that Glut4 mRNA expression is elevated in adipose tissue. Improved insulin sensitivity has already been demonstrated by hyperinsulinaemic–euglycaemic clamp studies in B6-mice treated with FGF21, showing improvement in whole body insulin sensitivity, which is accounted for an increase in glucose uptake into skeletal muscle and adipose tissue [45]. As a consequence, FGF21-treated carbohydrate-fed mice show normal blood glucose levels.

In addition to the prevention of hyperglycaemia, which itself suppresses the beta cell loss, pancreatic islets are protected from glucolipotoxicity and cytokine-induced apoptosis by FGF21 treatment [19]. Since no effect of FGF21 on islet cell proliferation has been observed, it was concluded that preservation of beta cells and their functioning by FGF21 may contribute to the beneficial effects of FGF21 on glucose homeostasis [19]. We can speculate that the protective effect of FGF21 is not influencing the islet cytoarchitecture directly and that it is a secondary response to a prevention of glucolipotoxicity.

As recently shown in NZO mice [36], treatment with a glucagon-like peptide 1–oestrogen hybrid decreased food intake resulting in body weight loss (mainly body fat), preserved normoglycaemia, improved glucose tolerance and beta cell protection. FGF21 treatment improved glucose homeostasis without reducing daily food intake; rather, animals treated with FGF21 consumed more food when caloric intake was normalised to animal body weight. This is in concordance with earlier observations made in FGF21 transgenic mice [20] and after FGF21 administration [17, 26, 46], while no effect on food intake was observed in other studies [14, 41].

In particular, Coskun and colleagues provided evidence that the effects of FGF21 on blood glucose levels and body weight are decoupled [26]. It is unclear if FGF21 is modulating food intake directly or if the hyperphagic response is secondary to the increased EE and a compensatory response to resist weight loss.

It was demonstrated in recent studies that pharmacological FGF21 treatment acts both in the brain and directly on adipose tissue to increase EE, stimulate sympathetic outflow and up-regulate thermogenic markers in BAT and WAT [14, 17, 26, 41, 42]. Consistent with the previous findings in other animal models [14, 17, 26, 41, 46], FGF21 treatment in NZO mice increased the overall EE with comparable magnitudes during both dark and light cycles. Interestingly, EE was further elevated by FGF21 after switching to the carbohydrate-containing diet. Eventually, the increase in EE due to FGF21 is not caused by an increase in physical activity in these animals, which is in contrast to other studies demonstrating increased metabolic rate along with increased physical activity [46]. FGF21 is sufficient to stimulate browning of sWAT as assessed by mRNA expression of Ucp1 and the induction of gene expression associated with browning (Cidea, Dio2, Prdm16). This outcome is consistent with evidence that pharmacological FGF21 treatment increases EE, upregulates UCP1 and promotes sWAT browning [17, 41, 42, 47, 48]; without changing the gene expression of the FGF21 co-receptor β-klotho (Klb). This suggests that in diabetic mice the downregulation of Klb in BAT may not be FGF21 dependent.

Taken together, the above experiments produce four notable conclusions. (1) Consistent with recent studies showing that FGF21 improves glucose homeostasis in various obese mice models, we demonstrate superior efficacy of FGF21 in preventing the onset of diet-induced diabetes in male NZO mice. (2) This protective effect is not caused by hypophagia (NZO mice are hyperphagic) or loss of fat mass, but (3) rather by an increase in EE due to the browning of sWAT and more directed storage of lipids in fat tissue. Finally, (4) these data indicate that obesity does not induce FGF21 resistance in NZO mice. As such, these findings support the diabetes-susceptible NZO mouse as a potential animal model to study endogenous FGF21 actions with regard to the prevention of diabetes.

**Acknowledgements** The authors thank C. Gumz, A. Teichmann and K. Warnke of the German Institute of Human Nutrition (Potsdam-Rehbrücke, Germany) for their skilful technical assistance. The authors would like to thank the staff of the animal housing facility located at the Max Rubner Laboratory (Potsdam-Rehbrücke, Germany) for their skilful assistance and excellent technical support. Linguistic refinements of the text by C.D. Morrison and N. Kühn are gratefully acknowledged.

**Data availability** All relevant data are included in the article and/or the ESM files.

**Funding** The work was supported by the German Ministry of Education and Research and the Brandenburg State (DZD grant 82DZD00302; AS). TL was supported by LA 3042/3-1 and LA 3042/4-1 from the Deutsche Forschungsgemeinschaft (DFG).

**Duality of interest** The authors declare that there is no duality of interest associated with this manuscript.

**Contribution statement** TL, IW and JW made substantial contributions to acquisition of data. TL drafted the article. All authors made substantial contributions to analysis and interpretation of data, and revising the article critically for important intellectual content. TL, CB and AS made substantial contributions to conception and design. All authors gave final approval of the version to be published. AS is the guarantor of this work.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Thorens B (2013) The required beta cell research for improving treatment of type 2 diabetes. J Intern Med 270:203–214
2. Alejandro EU, Gregg B, Blandino-Rosano M, Cras-Meneur C, Bernal-Mizrachi E (2015) Natural history of beta-cell adaptation and failure in type 2 diabetes. Mol Asp Med 42:19–41
3. Laeger T, Henagan TM, Albarado DC et al (2014) FGF21 is an endocrine signal of protein restriction. J Clin Invest 124:3913–3922
4. Laeger T, Albarado DC, Burke SJ et al (2016) Metabolic responses to dietary protein restriction require an increase in FGF21 that is delayed by the absence of GCN2. Cell Rep 16:707–716
5. Potthoff MJ, Finck BN (2014) Head over hepatocytes for FGF21. Diabetes 63:4013–4015
6. Morrison CD, Laeger T (2015) Protein-dependent regulation of feeding and metabolism. Trends Endocrinol Metab 26:256–262
7. Solon-Biet SM, Cogger VC, Pulpitel T et al (2016) Defining the nutritional and metabolic context of FGF21 using the geometric framework. Cell Metab 24:555–565
8. Kurosu H, Choi M, Ogawa Y et al (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282:26687–26695
9. Adams AC, Coskun T, Rovira AR et al (2012) Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 7:e38438
10. Kharitonenkov A, Dunbar JD, Bina HA et al (2008) FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 215:1–7
11. Goetz R, Ohnishi M, Ding X et al (2016) Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol Cell Biol 32:1944–2014
12. Markan KR, Potthoff MJ (2016) Metabolic fibroblast growth factors (FGFs): mediators of energy homeostasis. Semin Cell Dev Biol 53:85–93
13. Fisher EM, Maratos-Flier E (2016) Understanding the physiology of FGF21. Annu Rev Physiol 78:223–241
14. Adams AC, Yang C, Coskun T et al (2012) The breadth of FGF21’s metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab 2:31–37
15. Ge X, Chen C, Hui X, Wang Y, Lam KS, Xu A (2011) Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J Biol Chem 286:34533–34541
16. Gimeno RE, Moller DE (2014) FGF21-based pharmacotherapy—potential utility for metabolic disorders. Trends Endocrinol Metab 25:303–311
17. Sarruf DA, Thaler JP, Morton GJ et al (2010) Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 59:1817–1824
18. Kharitonenkov A, DiMarchi R (2017) Fibroblast growth factor 21 night watch: advances and uncertainties in the field. J Intern Med 281(3):233–246
19. Wente W, Efanov AM, Brenner M et al (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55:2470–2478
20. Kharitonenkov A, Shiyanova TL, Koester A et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:1627–1635
21. Singhal G, Fisher FM, Chee MJ et al (2016) Fibroblast growth factor 21 (FGF21) protects against high fat diet induced inflammation and islet hyperplasia in pancreas. PLoS One 11:e0148252
22. Xu J, Stanislaus S, Chinnokoswong N et al (2009) Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models—association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 297:E1105–E1114
23. Kharitonenkov A, DiMarchi R (2015) FGF21 revolutions: recent advances illuminating FGF21 biology and medicinal properties. Trends Endocrinol Metab 26:608–617
24. Fisher FM, Chui PC, Antonellis PJ et al (2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59:2781–2789
25. Zhang X, Yeung DC, Karpisek M et al (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246–1253
26. Coskun T, Bina HA, Schneider MA et al (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018–6027
27. Chen WW, Li L, Yang GY et al (2008) Circulating FGF-21 levels in normal subjects and in newly diagnosed patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116:65–68
28. Dushay J, Chui PC, Gopalakrishnan GS et al (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139:456–463
29. Nygaard EB, Moller CL, Kivelit P, Grove KL, Andersen B (2014) Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta). Int J Obes 38:183–191
30. Markan KR, Naber MC, Small SM, Peltekian L, Kessler RL, Potthoff MJ (2017) FGF21 resistance is not mediated by downregulation of beta-klotho expression in white adipose tissue. Mol Metab 6:602–610
31. Hale C, Chen MM, Stanislaus S et al (2012) Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology 153:69–80
32. Adams AC, Halstead CA, Hansen BC et al (2013) LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS One 8:e65763
33. Kluth O, Matzke D, Kamitz A et al (2015) Identification of four mouse diabetes candidate genes altering beta-cell proliferation. PLoS Genet 11:e1005506
34. Kluth O, Matzke D, Schulze G, Schwenk RW, Joost H, Schurmanna A (2014) Differential transcriptional analysis of diabetes-resistant and -sensitive mouse islets reveals significant overlap with human diabetes susceptibility genes. Diabetes 63:4230–4238
35. Kluth O, Mirhashemi F, Scheermack S et al (2011) Dissociation of lipotoxicity and glucotoxicity in a mouse model of obesity-associated diabetes: role of forkhead box O1 (FOXO1) in glucose-induced beta cell failure. Diabetologia 54:605–616
36. Schwenk RW, Baumeier C, Fian B et al (2015) GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia 58:604–614
37. Baumeier C, Kaiser D, Heeren J et al (2015) Caloric restriction and intermittent fasting alter hepatic lipid droplet proteome and diacylglycerol species and prevent diabetes in NZO mice. Biochim Biophys Acta 1851:566–575
38. Hesse D, Jaschke A, Kanzleiter T et al (2012) GTPass ARFRP1 is essential for normal hepatic glycogen storage and insulin-like growth factor 1 secretion. Mol Cell Biol 32:4363–4374
39. Jurgens HS, Neschen S, Ortmann S et al (2007) Development of diabetes in obese, insulin-resistant mice: essential role of dietary carbohydrate in beta cell destruction. Diabetologia 50:1481–1489
40. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470
41. Douris N, Stevanovic DM, Fisher FM et al (2015) Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice. Endocrinology 156:2470–2481
42. Fisher FM, Kleiner S, Douris N et al (2012) FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 26:271–281
43. Lin Z, Tian H, Lam KS et al (2013) Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 17:779–789
44. Kharitonenkov A, Wroblewski VJ, Koester A et al (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774–781
45. Camporez JP, Jornayvaz FR, Petersen MC et al (2013) Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 154:3099–3109
46. Xu J, Lloyd DJ, Hale C et al (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250–259
47. Galman C, Lundasen T, Kharitonenkov A et al (2008) The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 8:169–174
48. Owen BM, Ding X, Morgan DA et al (2014) FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 20:670–677